Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
A biomaterial is any material, natural or man-made, that comprises whole or part of a living structure or biomedical device which performs, auguments, or replaces a natural function'. A biomaterial is essentially a material that is used and adapted for a medical application. Biomaterials can have a benign function, such as being used for a heart valve, or may be bioactive . Used for a more interactive purposes such as implants. The links shown on this page feature the key word ′Biomaterial’ in their stories:
Asia Pacific dental biomaterials market grows at seven percent to 2016
Medical technology market intelligence analyst, Millennium Research Group (MRG), is forecasting that despite the Japanese tsunami's negative effect on market revenues, the Asia Pacific dental biomaterials market will grow moderately at an average annual rate of 6.6 percent through 2016, due to the
US wound care biomaterials market to expands to USD2.8bn by 2016
The growing population suffering from obesity, diabetes and hypertension will lead to increased incidence of both acute and chronic wounds, and favour adoption of wound care biomaterials in the USA forecasts market intelligence analyst, Millennium Research Group (MRG).
Medisse completes biocompatibility evaluation of resorbable biomaterial
Medisse, a medical device company focused on the development of a new generation of resorbable flexible implants, completes the biocompatibility evaluation of its novel resorbable FlexiSurge biomaterial in accordance with the international ISO 10993 standards.
Medtronic acquires chitosan-dextran gel technology for future FESS developments
Medtronic completes the purchase of rights to a chitosan-dextran gel technology from Adelaide Research and Innovation (the commercial development company of the University of Adelaide) in Australia, Robinson Squidgel, and Otago Innovation (a University of Otago company) in New Zealand.
Medtronic acquires Osteotech to boost regenerative biologics performance
Medtronic completes the acquisition of Osteotech, following payment of $6.50 per share in cash for each share of Osteotech stock, with a total transaction value of approximately $123 million.
Medtronic agrees to acquire Osteotech
Medtronic and Osteotech sign a definitive agreement which will see Medtronic acquire Osteotech for $6.50 per share in cash for each share of Osteotech common stock.
Biomerix biomaterial manufacturing sites receive ISO 13485 recognition
Biomerix, a medical technologies company developing products using its novel Biomerix Biomaterial, a three-dimensional scaffold for biointegrative tissue repair, receives an ISO 13485 Certificate of Regis
Study spotlights the osteoconductive properties of Trabecular Metal Technology
Data has been released from an independent 10-year comparative clinical study that demonstrates the osteoconductive properties of Zimmer's Trabecular Metal Technology.
Medtronic introduces PEEK-based interspinous process decompression device
Medtronic has announced the US launch of the X-STOP PEEK IPD System, the first interspinous process decompression (IPD) device approved by the US FDA that offers a PEEK-Bone interface for treating the symptoms of lumbar spinal stenosis (LSS).
New polymer material stops bone bleeding and reduced surgical infection risks
Ostene, a new polymer material developed by Ceremed to stop bone bleeding in surgery has been shown to reduce the risk of surgical infection according to a new research study.
Angiotech and Symphony Medical reach biomaterials agreement
Angiotech Pharmaceuticals and Symphony Medical have entered into an exclusive licensing agreement to employ one of Angiotech's proprietary PEG-based biomaterials as part of a prophylactic therapy that mitigates the onset of post-operative atrial fibrillation (POAF) for patients undergoing coronary a
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo